ERBB2 and breast cancer: In the LANDSCAPE trial, 45 patients with brain metastases from HER2+ breast cancer received lapatinib plus capecitabine prior to radiation therapy, reported a CNS objective response of 67%, with a median time to tumor progression of 5.5 months [9].